Suppr超能文献

推动急性肾损伤创新转化研究。

Enabling innovative translational research in acute kidney injury.

机构信息

Department of Medicine, Division of Nephrology, Nephrology Research and Training Center and Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

出版信息

Clin Transl Sci. 2012 Feb;5(1):93-101. doi: 10.1111/j.1752-8062.2011.00302.x. Epub 2011 Dec 7.

Abstract

Acute kidney injury (AKI) is a common, heterogeneous, and detrimental clinical condition that has significant attributable morbidity and mortality. Despite major advances in understanding the epidemiology, pathogenesis, and outcomes of AKI, preventive measures remain inadequate and therapeutic approaches (except for renal replacement therapy) have largely proven futile so far. Critical to the process of designing rational therapies is translational research, which involves the transition between the basic research discoveries and everyday clinical applications to prevent, diagnose, and treat human diseases. Progress in innovative approaches has been hampered due in part to the reliance on functional markers (serum creatinine and blood urea nitrogen) that are neither sensitive nor specific to diagnose AKI. This limitation has created a great deal of interest and intense investigation to identify a "troponin-like marker" that would facilitate recognition of AKI and allow for timely implementation of the precise therapeutic agent. The other major obstacle in this field is the diverse and complex nature of AKI that involves multiple independent and overlapping pathways, making it difficult to cure AKI with a single approach. In this review, we will summarize the advances, ongoing studies, and future perspectives in the field of translational research of AKI.

摘要

急性肾损伤(AKI)是一种常见的、异质性的、有害的临床病症,具有显著的可归因发病率和死亡率。尽管在理解 AKI 的流行病学、发病机制和结局方面取得了重大进展,但预防措施仍然不足,治疗方法(除了肾脏替代疗法外)迄今为止基本上都没有效果。设计合理治疗方法的关键是转化研究,它涉及基础研究发现与日常临床应用之间的转变,以预防、诊断和治疗人类疾病。创新方法的进展受到阻碍,部分原因是依赖于功能标志物(血清肌酐和血尿素氮),这些标志物既不敏感也不特异,无法诊断 AKI。这一局限性引起了极大的兴趣和深入的研究,以确定一种“肌钙蛋白样标志物”,这将有助于识别 AKI,并及时实施精确的治疗剂。该领域的另一个主要障碍是 AKI 的多样性和复杂性,涉及多个独立和重叠的途径,因此很难用单一方法治愈 AKI。在这篇综述中,我们将总结 AKI 转化研究领域的进展、正在进行的研究和未来展望。

相似文献

1
Enabling innovative translational research in acute kidney injury.推动急性肾损伤创新转化研究。
Clin Transl Sci. 2012 Feb;5(1):93-101. doi: 10.1111/j.1752-8062.2011.00302.x. Epub 2011 Dec 7.
4
Current concepts and advances in biomarkers of acute kidney injury.急性肾损伤生物标志物的当前概念和进展。
Crit Rev Clin Lab Sci. 2021 Aug;58(5):354-368. doi: 10.1080/10408363.2021.1879000. Epub 2021 Feb 8.
5
The need for disruptive innovation in acute kidney injury.急性肾损伤中颠覆性创新的必要性。
Clin Exp Nephrol. 2020 Nov;24(11):979-988. doi: 10.1007/s10157-020-01920-w. Epub 2020 Jun 24.
6
Biomarkers in acute kidney injury (AKI).急性肾损伤 (AKI) 的生物标志物。
Best Pract Res Clin Anaesthesiol. 2017 Sep;31(3):331-344. doi: 10.1016/j.bpa.2017.10.003.
7
Acute kidney injury: current perspectives.急性肾损伤:当前观点。
Postgrad Med. 2010 Nov;122(6):29-40. doi: 10.3810/pgm.2010.11.2220.

引用本文的文献

7
UAB-UCSD O'Brien Center for Acute Kidney Injury Research.UAB-UCSD 奥布莱恩急性肾损伤研究中心。
Am J Physiol Renal Physiol. 2021 May 1;320(5):F870-F882. doi: 10.1152/ajprenal.00661.2020. Epub 2021 Mar 29.

本文引用的文献

7
The aging kidney: physiological changes.衰老的肾脏:生理变化。
Adv Chronic Kidney Dis. 2010 Jul;17(4):302-7. doi: 10.1053/j.ackd.2010.05.002.
9
Biomarkers in acute myocardial infarction.急性心肌梗死的生物标志物。
BMC Med. 2010 Jun 7;8:34. doi: 10.1186/1741-7015-8-34.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验